0.431
1.82%
-0.008
Handel nachbörslich:
.44
0.009
+2.09%
Schlusskurs vom Vortag:
$0.439
Offen:
$0.439
24-Stunden-Volumen:
26,838
Relative Volume:
0.08
Marktkapitalisierung:
$5.96M
Einnahmen:
$122.10K
Nettoeinkommen (Verlust:
$-13.77M
KGV:
-0.5671
EPS:
-0.76
Netto-Cashflow:
$-4.79M
1W Leistung:
-13.78%
1M Leistung:
-21.64%
6M Leistung:
-58.56%
1J Leistung:
-28.17%
Ainos Inc Stock (AIMD) Company Profile
Firmenname
Ainos Inc
Sektor
Branche
Telefon
858-869-2986
Adresse
AINOS, INC., SAN DIEGO
Vergleichen Sie AIMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
AIMD | 0.431 | 5.96M | 122.10K | -13.77M | -4.79M | -0.76 |
ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Ainos Inc Aktie (AIMD) Neueste Nachrichten
AIMD Stock Hits 52-Week Low at $0.4 Amid Market Challenges - Investing.com Canada
AIMDAinos, Inc. Latest Stock News & Market Updates - StockTitan
Ainos (AIMD) Advances VELDONA Trial for Sjogren's: Key IRB Approval Secured, 28 Patents Added | AIMDW Stock News - StockTitan
Ainos, Inc. (NASDAQ:AIMD) Sees Large Decline in Short Interest - Defense World
Ainos Advances Sjögren's Treatment: Key Trial for VELDONA® Gets IRB Green Light | AIMDW Stock News - StockTitan
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023) - Yahoo Finance
Ainos reports unusual stock activity to regulators - Investing.com India
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - WICZ
Ainos reports unusual stock activity to regulators By Investing.com - Investing.com UK
Ainos (AIMD) Alerts SEC to Suspicious Trading Activity, Demands Investigation | AIMDW Stock News - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 14.7% – Here’s Why - Defense World
Ainos Reports Third Quarter 2024 Financial Results - StockTitan
Behcet's syndrome Treatment Market 2034: Clinical Trials, EMA, - openPR
Ainos stock plunges to 52-week low of $0.45 amid steep annual decline - Investing.com
Analyzing CONMED (NYSE:CNMD) & Ainos (OTCMKTS:AIMD) - Defense World
Ainos, Inc. (NASDAQ:AIMD) Short Interest Down 37.6% in October - Defense World
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets - StockTitan
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast - StockTitan
Ainos Inc. secures exclusive patent rights in new deal - Investing.com
Ainos Inc. secures exclusive patent rights in new deal By Investing.com - Investing.com UK
Ainos (OTCMKTS:AIMD) Stock Price Down 8.7% – Here’s Why - Defense World
Ainos Leverages AI Nose for Safer, Smarter Factories - MSN
Financial Health Report: Ainos Inc (AIMD)’s Ratios Tell a Tale - The Dwinnex
Cutera (CUTR) Stock Drops 5.14% Amid Financial Challenges - GuruFocus.com
Ainos Inc. secures stockholder nod for special stock awards - Investing.com
Ainos planning Phase 3 study of low-dose interferon-alpha for primary Sjögren’s - Sjogren's Syndrome News
AIMDWAinos, Inc. Warrants Latest Stock News & Market Updates - StockTitan
Ainos Inc (AIMD) Stock: A Year of Highs and Lows - The InvestChronicle
Ainos receives IRB nod for HIV-related oral wart trial - Investing.com India
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA - StockTitan
Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome - StockTitan
Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options - StockTitan
Esperion Therapeutics (NASDAQ:ESPR) versus Ainos (NASDAQ:AIMD) Critical Analysis - Defense World
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts - StockTitan
AIMD stock touches 52-week low at $0.45 amid market challenges - Investing.com
Ainos set for clinical trial of HIV treatment at Taiwan hospital - Investing.com
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA - StockTitan
Financial Review: Ainos (OTCMKTS:AIMD) versus Siemens Healthineers (OTCMKTS:SMMNY) - Defense World
Ainos (NASDAQ:AIMD) Shares Down 6.6% - Defense World
Ainos secures Taiwan patent for antiviral drug VELDONA - Investing.com
Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention - Lelezard
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Ainos (OTCMKTS:AIMD) Stock Price Up 6.1% - Defense World
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter - PharmiWeb.com
Ainos Inc (AIMD) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Is the Ainos Inc (NASDAQ:AIMD) stock an investment opportunity? - US Post News
Ainos AI Nose achieves 79% accuracy in VOC detection - Investing.com India
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety - AccessWire
Ainos Unveils AI Nose Breakthrough that Revolutionizes - GlobeNewswire
Ainos reports 79% identification accuracy of AI Nose - TipRanks
Ainos, Inc. (NASDAQ:AIMD) Short Interest Update - Defense World
Finanzdaten der Ainos Inc-Aktie (AIMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):